Investigational drug · Phase 2
Petrelintide
Also called: ZP8396
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Autism Spectrum Disorder (ASD, Overweight.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
5
Any phase or sponsor naming "Petrelintide"
First trial start
2024
Dec 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Petrelintide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Autism Spectrum Disorder (ASD
- Overweight
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Petrelintide" as an intervention, largest first.
- Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesPivotal-lookingCompleted
Zealand PharmaIndustry
NCT06662539 · 493 participants · Start Dec 9, 2024 · Primary completion Sep 30, 2025
Drug: Petrelintide; Placebo · For: Obesity
Sites: Birmingham, Alabama; Boca Raton, Florida; Clearwater, Florida · 32 sites in all
- Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)Pivotal-lookingCompleted
Zealand PharmaIndustry
NCT06926842 · 221 participants · Start Apr 22, 2025 · Primary completion Aug 13, 2026
Drug: Petrelintide · For: Overweight; Type 2 Diabetes; Obesity
Sites: Cullman, Alabama; Chandler, Arizona; Phoenix, Arizona · 48 sites in all
- Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsCompleted
Zealand PharmaIndustry
NCT07338214 · 48 participants · Start Dec 17, 2025 · Primary completion Mar 31, 2026
Drug: Petrelintide · For: Obesity & Overweight
Sites: Berlin, Germany
Zealand PharmaIndustry
NCT07076030 · 39 participants · Start Apr 15, 2025 · Primary completion Nov 25, 2025
Drug: Petrelintide · For: Renal Impairment
Sites: Berlin, Germany
Zealand PharmaIndustry
NCT07682818 · 36 participants (planned) · Start May 18, 2026 · Primary completion Apr 12, 2027
Drug: Petrelintide · For: Impaired Hepatic Function
Sites: Wroclaw, Poland; Bratislava, Slovakia; Malacky, Slovakia
Newest research
PubMed records naming it or its code names, newest first.
- Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Garvey WT, Ard J, Connery L, et al. · Lancet Diabetes Endocrinol 2026
- Petrelintide and the evolving role of amylin agonism in obesity.
Madsbad S, Holst JJ · Lancet Diabetes Endocrinol 2026
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.
Fischer SL, Borner T · Pharmacol Res 2026
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi A, le Roux CW · Diabetes Obes Metab 2026
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.
Brændholt Olsen M, Griffin J, Hövelmann U, et al. · Diabetes Obes Metab 2026
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Bailey CJ, Flatt PR, Conlon JM · Peptides 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.